Abeprazan
As of the edition of 20 October 2026, Abeprazan is a small molecule: in active development; acts on ATP4A and ATP4B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 33, 0 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 3 | 2 | 0 |
| Phase 1 | 13 | 5 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 10 | 5 | 2 | 0 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 33 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daewoong | Lead sponsor of trials | 2016 to now |